4D Molecular Therapeutics (FDMT) Cash from Financing Activities (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Cash from Financing Activities data on file, last reported at $11.5 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $11.5 million in Q1 2026; TTM through Mar 2026 was $124.4 million, a 575.67% increase from a year earlier, with the FY2025 full-year figure at $113.0 million, down 66.51% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $11.5 million, down from $112.0 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for FDMT reached as high as $318.8 million in Q1 2024 and fell as low as -$50000.0 in Q2 2022.
• Historically, Cash from Financing Activities has averaged $38.9 million across 5 years, with a median of $3.4 million in 2022.
• Across the five-year window, Cash from Financing Activities sank 106.1% in 2022 and soared 261138.0% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at $2.0 million in 2022, then soared by 132.75% to $4.8 million in 2023, then plunged by 87.38% to $601000.0 in 2024, then soared by 18532.61% to $112.0 million in 2025, then plunged by 89.74% to $11.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $11.5 million in Q1 2026, $112.0 million in Q4 2025, and $116000.0 in Q3 2025.